Retevmo

Chemical Nameselpercatinib
Dosage FormCapsules (oral; 40 mg, 80 mg)
Drug ClassKinase inhibitors
SystemRespiratory, Endocrine
CompanyLilly USA
Approval Year2020

Indication

  • For the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC).
  • For the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
  • For the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
Last updated on 12/8/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Retevmo (selpercatinib) Prescribing Information.2020Lilly USA, LLC, Indianapolis, IN